NCT00451048 · OUTCOME

Number Participants With Complete, Partial or Hematologic Improvement Response

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia · Source last updated 2018-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI)

Analysis population: No patient achieved CR, PR or HI as response.

Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown. sunitinib malate: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I	10

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI)

groups

param Type

NUMBER

population Description

No patient achieved CR, PR or HI as response.

reporting Status

POSTED

time Frame

Up to 6 years

title

Number Participants With Complete, Partial or Hematologic Improvement Response

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice